Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Diagnostic and Therapeutic Use of Microbiota to Soon Become Reality

By LabMedica International staff writers
Posted on 18 Jun 2025

Despite the growing body of research linking the gut microbiome to a range of diseases, its clinical application remains limited due to biological complexity, methodological constraints, and gaps in communication between researchers and physicians. More...

The microbiome holds promise for diagnostics, such as colon cancer screening and predicting immunotherapy response, as well as for therapeutic uses like microbiota transplants and engineered probiotics. A new article published in Cell outlines a roadmap to bridge these challenges and guide doctors in translating microbiome research into real-world clinical practice.

The article, authored by a team of physician-scientists from Agostino Gemelli University Policlinic (Rome, Italy) and the Catholic University (Milan, Italy), aims to serve as a practical reference for clinicians. It summarizes current knowledge from microbiome studies and outlines how these insights can be applied in diagnostics and treatment. It also addresses the key barriers preventing this progress: a lack of standardization, inadequate clinical trial design, limited large-scale studies, and a cultural gap in clinician familiarity with microbiome science. According to the authors, the microbiome’s diagnostic and therapeutic potential is broad but remains underused due to difficulties in establishing direct causal links between microbiota composition and disease. Variability in individual microbiomes and external factors like diet and medication use complicate clinical study design.

Moreover, there is a lack of harmonized testing protocols, and most studies are single-center and small-scale, restricting wider application. The authors also note a major gap in interdisciplinary communication, which slows translation of lab research into clinical use. However, several promising applications are now approaching clinical viability. In diagnostics, microbiota composition could soon serve as a biomarker for early disease detection, particularly in colon cancer. It may also help distinguish between conditions such as ulcerative colitis and Crohn’s disease or predict a patient’s response to immunotherapy, especially in lung cancer and melanoma. On the therapeutic front, microbiota transplantation—already in use for Clostridium difficile infections—is evolving toward refined microbial cocktails. Other avenues include the use of lytic bacteriophages to target drug-resistant bacteria and engineered probiotics that produce or deliver therapeutic compounds.

To accelerate the adoption of microbiome-based tools, the authors propose several concrete actions: standardizing microbiota test reporting across labs, improving clinical trial design, aligning basic research with clinical needs, and training doctors to interpret and use microbiome data. Among the first expected clinical applications is a colon cancer screening test combining fecal occult blood testing with microbiota analysis to guide decisions about colonoscopy. Similarly, a test to predict cancer immunotherapy response based on microbiota profiles is also nearing readiness for clinical use. On the therapeutic front, future targets include using microbiota to eradicate multidrug-resistant infections such as intestinal Klebsiella, particularly in high-risk patients awaiting organ transplants. Over the long term, microbiome alterations could help boost the effectiveness of immunotherapies in cancer care.

“Despite a huge amount of research and studies on the microbiome, clinical applications are still very scarce, sometimes not entirely orthodox, sometimes “primitive”, said Dr. Gianluca Ianiro, researcher in Gastroenterology at the Catholic University and medical director of the Gastroenterology Unit at the Gemelli IRCCS Polyclinic. “But this will soon change, because the microbiome is the perfect target for precision medicine, specific to each individual and variable in composition depending on life events and diet."


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.